[Thrombolytic agents in myocardial infarction: results of large mortality studies].
Large studies involving several thousand patients have clearly established the effectiveness of thrombolytic therapy in reducing mortality in the acute phase of myocardial infarction: the earlier the treatment, the greater this reduction. The value of late thrombolysis remains to be determined by further studies. This technique can be extended to the oldest subjects who benefit most from this type of treatment, bearing in mind that they are at a greater risk of neurological complications. The effectiveness of thrombolysis is partially dissociated from its effects on left ventricular function. Since the thrombolytic agents (streptokinase, anistreplase and recombinant tissue plasminogen activator) are equally effective in reducing mortality and neurological complications, it seems reasonable to use the cheapest of these drugs as initial treatment, except in some special cases.
Slama
M S
MS
Service de cardiologie, hôpital Antoine-Béclère, Clamart.
Motté
G
G
D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D005602:France / Q000453:epidemiology; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D009422:Nervous System Diseases / Q000139:chemically induced / Q000453:epidemiology
D005343:Fibrinolytic Agents
Les thrombolytiques dans l'infarctus du myocarde: résultats des grandes études de mortalité.